Stage designation | Molecular findings in patients with early endometrial cancer (stages I and II after surgical staging) |
Stage IAmPOLEmut | POLEmut endometrial carcinoma, confined to the uterine corpus or with cervical extension, regardless of the degree of LVSI or histological type |
Stage IICmp53abn | p53abn endometrial carcinoma confined to the uterine corpus with any myometrial invasion, with or without cervical invasion, and regardless of the degree of LVSI or histological type |
LVSI: lymphovascular space involvement; MMRd: mismatch repair deficiency; NSMP: no specific molecular profile; p53abn: p53 abnormal.
* When feasible, the addition of molecular subtype to the staging criteria allows a better prediction of prognosis in a staging/prognosis scheme. The performance of complete molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged in all cases of endometrial cancer for prognostic risk-group stratification and as potential influencing factors of adjuvant or systemic treatment decisions. Molecular subtype assignment can be done on a biopsy, in which case it need not be repeated on the hysterectomy specimen. When performed, these molecular classifications should be recorded in all stages.When the molecular classification is known:
Do you want to add Medilib to your home screen?